BACKGROUND: This study was designed to improve identification of human blood monocytes by using antibodies to molecules that occur consistently on all stages of monocyte development and differentiation. METHODS: We examined blood samples from 200 healthy adults without clinically diagnosed immunological abnormalities by flow cytometry (FCM) with multiple combinations of antibodies and with a hematology analyzer (Beckman LH750). RESULTS: CD91 (α2 -macroglobulin receptor) was expressed only by monocytes and to a consistent level among subjects [mean median fluorescence intensity (MFI) = 16.2 ± 3.2]. Notably, only 85.7 ± 5.82% of the CD91(+) monocytes expressed high levels of the classical monocyte marker CD14, with some CD91(+) CD16(+) cells having negligible CD14, indicating that substantial FCM under-counts will occur when monocytes are identified by high CD14. CD33 (receptor for sialyl conjugates) was co-expressed with CD91 on monocytes but CD33 expression varied by nearly ten-fold among subjects (mean MFI = 17.4 ± 7.7). In comparison to FCM analyses, the hematology analyzer systematically over-counted monocytes and eosinophils while lymphocyte and neutrophil differential values generally agreed with FCM methods. CONCLUSIONS: CD91 is a better marker to identify monocytes than CD14 or CD33. Furthermore, FCM (with anti-CD91) identifies monocytes better than a currently used clinical CBC instrument. Use of anti-CD91 together with anti-CD14 and anti-CD16 supports the identification of the diagnostically significant monocyte populations with variable expression of CD14 and CD16.
BACKGROUND: This study was designed to improve identification of human blood monocytes by using antibodies to molecules that occur consistently on all stages of monocyte development and differentiation. METHODS: We examined blood samples from 200 healthy adults without clinically diagnosed immunological abnormalities by flow cytometry (FCM) with multiple combinations of antibodies and with a hematology analyzer (Beckman LH750). RESULTS:CD91 (α2 -macroglobulin receptor) was expressed only by monocytes and to a consistent level among subjects [mean median fluorescence intensity (MFI) = 16.2 ± 3.2]. Notably, only 85.7 ± 5.82% of the CD91(+) monocytes expressed high levels of the classical monocyte marker CD14, with some CD91(+) CD16(+) cells having negligible CD14, indicating that substantial FCM under-counts will occur when monocytes are identified by high CD14. CD33 (receptor for sialyl conjugates) was co-expressed with CD91 on monocytes but CD33 expression varied by nearly ten-fold among subjects (mean MFI = 17.4 ± 7.7). In comparison to FCM analyses, the hematology analyzer systematically over-counted monocytes and eosinophils while lymphocyte and neutrophil differential values generally agreed with FCM methods. CONCLUSIONS:CD91 is a better marker to identify monocytes than CD14 or CD33. Furthermore, FCM (with anti-CD91) identifies monocytes better than a currently used clinical CBC instrument. Use of anti-CD91 together with anti-CD14 and anti-CD16 supports the identification of the diagnostically significant monocyte populations with variable expression of CD14 and CD16.
Authors: David A Hume; Ian L Ross; S Roy Himes; R Tedjo Sasmono; Christine A Wells; Timothy Ravasi Journal: J Leukoc Biol Date: 2002-10 Impact factor: 4.962
Authors: Tamás Ordög; Doug Redelman; Viktor J Horváth; Lisa J Miller; Burton Horowitz; Kenton M Sanders Journal: Cytometry A Date: 2004-12 Impact factor: 4.355
Authors: Alexander P Sung; Jennifer J-J Tang; Michael J Guglielmo; Julie Smith-Gagen; Lucinda Bateman; Lydia Navarrete-Galvan; Doug D Redelman; Dorothy Hudig Journal: Fatigue Date: 2021-02-02
Authors: Eric Daniel Avila-Calderón; Jorge Erick Otero-Olarra; Leopoldo Flores-Romo; Humberto Peralta; Ma Guadalupe Aguilera-Arreola; María Rosario Morales-García; Juana Calderón-Amador; Olin Medina-Chávez; Luis Donis-Maturano; María Del Socorro Ruiz-Palma; Araceli Contreras-Rodríguez Journal: Front Microbiol Date: 2018-11-16 Impact factor: 5.640